DBVT News and Press, DBV Technologies S.A.

2026-06-30 10:15:07 ET H.C. Wainwright analyst issues BUY recommendation for DBVT on June 30, 2026 01:30PM ET. The previous analyst recommendation was Buy. DBVT was trading at $15.905 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2026-06-30 09:42:09 ET DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children June 29, 2026 5:00 PM EDT... Read the full article on Seeking Alpha For further details see: DBV Technologies S.A. (DBVT) Discusses...

Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing DBV has been engaged in extensive discussions ...

Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announ...

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “ Company ”), a late-stage biopharmace...

Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placeb...

Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “ Company ”), a late-stage biopharmaceutical...

Information Regarding the Total Number of Voting Rights and  Total Number of Shares of the Company as of May 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 * Net tota...

Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late stage biopharmaceutica...

Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating the efficacy and safety of the VIASKIN ® Peanut P...